VIDEO: StableVisc shows positive outcomes in FDA study
Key takeaways:
- In an FDA study, StableVisc was noninferior to the comparator.
- A lower incidence of postoperative IOP spikes was found with StableVisc.
SAN DIEGO — In this Healio Video Perspective from the ASCRS meeting, Mitchell C. Shultz, MD, speaks about the results of the FDA clinical trial on StableVisc, a new viscoelastic agent for cataract surgery from Bausch + Lomb.
The ophthalmic viscosurgical device is made up of 1% hyaluronic acid combined with sorbitol, which adds to the ability to remove free radicals from the anterior chamber, improving postoperative day 1 clarity of the cornea.
In the study, StableVisc was not inferior to the comparator ProVisc (Alcon), was equally safe in terms of endothelial cell loss, and had a lower incidence of postoperative IOP spikes of 30 mm Hg or more at all time points (5% vs. 8%).
“Personally and anecdotally, I also found that it was easier to remove this product when compared to the ProVisc product. The product comes out of the eye in approximately 7 seconds, which is really fast,” Shultz said.
Collapse
Stephenson PDG, et al. Safety and effectiveness comparison of a new cohesive ophthalmic viscosurgical device (OVD). Presented at: American Society of Cataract and Refractive Surgery meeting; May 5-8, 2023; San Diego.
Read more about